Sinovac’s candidate – dubbed CoronaVac – induced a positive immune response against COVID-19, according to a statement released by the Chinese biotech company.
The early-stage trials tested the candidate in 743 healthy volunteers between 18 and 59 years of age. That included 143 participants in a phase 1 trial and 600 volunteers in a phase 2 trial.
In the 600-patient phase 2 study, CoronaVac induced neutralising antibodies in ‘above 90%’ of volunteers who were tested 14 days after receiving two doses of the vaccine, two weeks apart.
According to Sinovac, the vaccine did not demonstrate any severe side effects among the volunteers across both trials.
Following the initial results, Sinovac plans to submit a phase 2 clinical study report and a phase 3 clinical study protocol to China’s National Medical Products Administration (NMPA). The company also expects to begin applications for phase 3 clinical trials outside China…